Clinical Trials
4 trialsNCT01746836 2026-03-09
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04160546 2024-12-31
ResToP
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Active not recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03807479 2023-09-14
PONS
GWT-TUD GmbH
Phase 2 Terminated